Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 257 participants.

Also called NCT01644331

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 257 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01644331
Other papers using this trial's data
  • Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure Journal of the American College of Cardiology, 2017-03-21 DOI, PubMed 27654854

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01644331. Randomized; double masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2016-02 (actual). Results posted on 2017-04-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure
Acronym
TACTICS-HF
Condition
Heart Failure
Condition
Dyspnea
Intervention (Drug)
Tolvaptan
Intervention (Drug)
Placebo
Lead sponsor
Duke University (class: other)

Record details

Record id
cardio:ct-nct01644331
Content hash
067b80fd10a7d9377892d8cfc031966aa1d55fdbdda1f6505eabee3710cfad8e